Literature DB >> 18790760

hKSR-2, a vitamin D-regulated gene, inhibits apoptosis in arabinocytosine-treated HL60 leukemia cells.

Xuening Wang1, Rahul Patel, George P Studzinski.   

Abstract

Ras signaling can be modulated by the scaffolding activity of kinase suppressor of Ras-1 (KSR-1) and by the hKSR-2 protein, resulting in diverse phenotypic outcomes. The mitogen-activated protein kinase cascade downstream from Ras and KSRs includes Raf-1 and extracellular signal-regulated kinase 1/2 kinases, known to enhance survival potential of a range of cell types. Because the molecular events that increase survival of HL60 cells induced to differentiate toward monocytic phenotype by 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] are not known, we investigated if KSR proteins provide a survival function in these cells. We found that whereas kinase suppressor of Ras-1 had no detectable effect on cell survival in the system studied here, 1,25-(OH)2D3-induced up-regulation of hKSR-2 enhanced the resistance of HL60 cells to arabinocytosine. Knockdown of hKSR-2 by either small interfering RNA or antisense oligonucleotides increased arabinocytosine-induced apoptosis, which was accompanied by reduced Bcl-2/Bax and Bcl-2/Bad ratios, and increased caspase-3 activating cleavage. In contrast, up-regulation of Mcl-1 was not abrogated by anti-sense (AS) AS-hKSR-2, pointing to a specific role of Bcl-2 in control of 1,25-(OH)2D3-induced increased cell survival. These findings are consistent with the previously shown lack of fully differentiated monocytic cells in HL60 cultures exposed to 1,25-(OH)2D3 in which hKSR-2 was knocked down, suggesting that optimal differentiation of these cells requires enhanced antiapoptotic mechanisms provided, at least in part, by hKSR-2. Collectively, these results suggest that hKSR-2 may offer a new target for novel therapies of acute myelogenous leukemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18790760      PMCID: PMC2814415          DOI: 10.1158/1535-7163.MCT-08-0276

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  44 in total

Review 1.  Coordinating ERK/MAPK signalling through scaffolds and inhibitors.

Authors:  Walter Kolch
Journal:  Nat Rev Mol Cell Biol       Date:  2005-11       Impact factor: 94.444

2.  Induction of kinase suppressor of RAS-1(KSR-1) gene by 1, alpha25-dihydroxyvitamin D3 in human leukemia HL60 cells through a vitamin D response element in the 5'-flanking region.

Authors:  X Wang; T-T Wang; J H White; G P Studzinski
Journal:  Oncogene       Date:  2006-05-29       Impact factor: 9.867

3.  The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/EBP pathway.

Authors:  George P Studzinski; Xuening Wang; Yan Ji; Qing Wang; Yingyu Zhang; Andrzej Kutner; Jonathan S Harrison
Journal:  J Steroid Biochem Mol Biol       Date:  2005-07-25       Impact factor: 4.292

4.  Raf-1 signaling is required for the later stages of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells but is not mediated by the MEK/ERK module.

Authors:  Xuening Wang; George P Studzinski
Journal:  J Cell Physiol       Date:  2006-11       Impact factor: 6.384

5.  Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.

Authors:  Girija Dasmahapatra; Jorge A Almenara; Steven Grant
Journal:  Mol Pharmacol       Date:  2005-10-11       Impact factor: 4.436

6.  Kinase suppressor of Ras-1 protects intestinal epithelium from cytokine-mediated apoptosis during inflammation.

Authors:  Fang Yan; Sutha K John; Guinn Wilson; David S Jones; M Kay Washington; D Brent Polk
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

7.  Expression of kinase suppressor of Ras1 enhances cisplatin-induced extracellular signal-regulated kinase activation and cisplatin sensitivity.

Authors:  Min Kim; Ying Yan; Robert L Kortum; Scott M Stoeger; Magdalene K Sgagias; Kwangmoon Lee; Robert E Lewis; Kenneth H Cowan
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

8.  hKSR-2 inhibits MEKK3-activated MAP kinase and NF-kappaB pathways in inflammation.

Authors:  Padma L Channavajhala; Vikram R Rao; Vikki Spaulding; Lih-Ling Lin; Y George Zhang
Journal:  Biochem Biophys Res Commun       Date:  2005-09-09       Impact factor: 3.575

9.  Expression of human kinase suppressor of Ras 2 (hKSR-2) gene in HL60 leukemia cells is directly upregulated by 1,25-dihydroxyvitamin D(3) and is required for optimal cell differentiation.

Authors:  Xuening Wang; Tian-Tian Wang; John H White; George P Studzinski
Journal:  Exp Cell Res       Date:  2007-05-31       Impact factor: 3.905

10.  MCL-1, a member of the BLC-2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation.

Authors:  T Yang; H L Buchan; K J Townsend; R W Craig
Journal:  J Cell Physiol       Date:  1996-03       Impact factor: 6.384

View more
  10 in total

1.  Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination.

Authors:  Xuening Wang; Jonathan S Harrison; George P Studzinski
Journal:  J Steroid Biochem Mol Biol       Date:  2015-08-28       Impact factor: 4.292

2.  The Nrf2 transcription factor is a positive regulator of myeloid differentiation of acute myeloid leukemia cells.

Authors:  Irene Bobilev; Victoria Novik; Itai Levi; Ofer Shpilberg; Joseph Levy; Yoav Sharoni; George P Studzinski; Michael Danilenko
Journal:  Cancer Biol Ther       Date:  2011-02-01       Impact factor: 4.742

3.  MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis.

Authors:  Elzbieta Gocek; Xuening Wang; Xiuping Liu; Chang-Gong Liu; George P Studzinski
Journal:  Cancer Res       Date:  2011-08-04       Impact factor: 12.701

Review 4.  Vitamin D and differentiation in cancer.

Authors:  Elzbieta Gocek; George P Studzinski
Journal:  Crit Rev Clin Lab Sci       Date:  2009       Impact factor: 6.250

5.  Tumor suppressor p53 status does not determine the differentiation-associated G₁ cell cycle arrest induced in leukemia cells by 1,25-dihydroxyvitamin D₃ and antioxidants.

Authors:  Thelma Thompson; Michael Danilenko; Lyubomir Vassilev; George P Studzinski
Journal:  Cancer Biol Ther       Date:  2010-08-13       Impact factor: 4.742

6.  1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.

Authors:  Thelma Thompson; Michael Andreeff; George P Studzinski; Lyubomir T Vassilev
Journal:  Mol Cancer Ther       Date:  2010-04-20       Impact factor: 6.261

7.  The transcriptomic response of mixed neuron-glial cell cultures to 1,25-dihydroxyvitamin d3 includes genes limiting the progression of neurodegenerative diseases.

Authors:  Marie-France Nissou; Jacques Brocard; Michèle El Atifi; Audrey Guttin; Annie Andrieux; François Berger; Jean-Paul Issartel; Didier Wion
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

8.  MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3.

Authors:  Xuening Wang; Elzbieta Gocek; Chang-Gong Liu; George P Studzinski
Journal:  Cell Cycle       Date:  2009-03-18       Impact factor: 4.534

9.  Attenuation of constitutive DNA damage signaling by 1,25-dihydroxyvitamin D3.

Authors:  H Dorota Halicka; Hong Zhao; Jiangwei Li; Frank Traganos; George P Studzinski; Zbigniew Darzynkiewicz
Journal:  Aging (Albany NY)       Date:  2012-04       Impact factor: 5.682

Review 10.  The Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia Therapy.

Authors:  Elzbieta Gocek; George P Studzinski
Journal:  J Clin Med       Date:  2015-03-25       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.